Cargando…

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review

Patient: Female, 50-year-old Final Diagnosis: Chronic myeloid leukaemia Symptoms: Dizziness • weakness Medication: — Clinical Procedure: — Specialty: Hematology OBJECTIVE: Unusual clinical course BACKGROUND: Although the V617F mutation in the Janus kinase 2 (JAK2) gene and the breakpoint cluster reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yue, Yanhua, Wei, Wei, Guo, Yanting, Wang, Fei, Dong, Weimin, Liu, Yue, Lin, Yan, Cao, Yang, Gu, Weiying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548110/ https://www.ncbi.nlm.nih.gov/pubmed/33021971 http://dx.doi.org/10.12659/AJCR.925151

Ejemplares similares

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
por: Ross, Theodora S, et al.
Publicado: (2014)

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia
por: Liu, Yonglan, et al.
Publicado: (2022)

New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
por: Sholikah, Tri Agusti, et al.
Publicado: (2017)

Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia
por: Gómez, Carmela, et al.
Publicado: (2022)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021)

Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia
por: Hai, Abdul, et al.
Publicado: (2014)

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
por: Samanta, A, et al.
Publicado: (2011)

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2021)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia
por: Narita, Miwako, et al.
Publicado: (2012)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia
por: Mukherjee, Kaushiki, et al.
Publicado: (2017)

BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
por: Paramita, Dewi Kartikawati, et al.
Publicado: (2020)

Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
por: Bang, Soo-Mee, et al.
Publicado: (2006)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

“Preleukemic or smoldering” chronic myelogenous leukemia (CML):BCR-ABL1 positive: A brief case report
por: Bennett, John M., et al.
Publicado: (2014)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia
Publicado: (2019)

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
por: Jiang, Shuoyi, et al.
Publicado: (2021)

Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2(V617F) Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
por: de Almeida Filho, T.P., et al.
Publicado: (2019)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

Trifolium Repens Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway
por: Sarno, Federica, et al.
Publicado: (2020)

Protocol for isolation and analysis of the leukemia stem cells in BCR-ABL-driven chronic myelogenous leukemia mice
por: Liu, Chang, et al.
Publicado: (2023)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
por: Yildiz, Ismail, et al.
Publicado: (2017)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Montecchini, Oksana, et al.
Publicado: (2021)

SOX6 blocks the proliferation of BCR-ABL1(+) and JAK2V617F(+) leukemic cells
por: Barbarani, Gloria, et al.
Publicado: (2019)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia
por: Maifrede, Silvia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pc6k0ul4mp561t3sqceass10t4